JNBA Financial Advisors Reduces Holdings in Pfizer Inc. (NYSE:PFE)

JNBA Financial Advisors decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 30.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,042 shares of the biopharmaceutical company’s stock after selling 3,440 shares during the period. JNBA Financial Advisors’ holdings in Pfizer were worth $233,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the 2nd quarter worth $29,000. Quarry LP purchased a new stake in Pfizer during the 2nd quarter worth $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer during the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the 1st quarter worth $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on PFE. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Trading Down 2.3 %

Shares of NYSE:PFE opened at $27.35 on Thursday. The company has a market cap of $154.98 billion, a PE ratio of 36.96, a P/E/G ratio of 0.88 and a beta of 0.67. The company’s 50-day moving average price is $28.96 and its 200 day moving average price is $28.64. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.14%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.